- RAMM Pharma (RAMM) has started trials to study the efficacy of its pet cannabinoid formulation
- The company hopes to use its proprietary NettaVet for treatment of four pathologies in animals
- The trials will be conducted in partnership with Universidad de la Republica de Uruguay
- The treatment covers three conditions pertaining to dogs, and one to horses
- RAMM Pharma is down 3.85 per cent, with shares of the company trading at C$1.00 at 10:56 am ET
RAMM Pharma (RAMM) has started trials to study the efficacy of its pet cannabinoid formulation.
The company hopes to use its proprietary NettaVet for treatment of four pathologies in animals.
The trials will be conducted in partnership with Universidad de la Republica de Uruguay.
Experts from Montreal University, the University of Buenos Aires, São Paulo State University and the University of Barcelona will also be involved.
The clinical trials will evaluate the efficacy of the cannabinoid formulations for the treatment of anxiety in dogs, chronic osteoarthritis pain in dogs, allergic dermatitis in dogs and chronic osteoarthritis pain in horses.
NettaLife is a wholly-owned subsidiary of RAMM, dedicated to the production, export and commercialization of pet products, food, pharmaceutical specialties and cosmetic products for animals.
“We are pleased to commence this initial set of clinical trials with renowned experts to advance the development of products to help address some of the most common animal ailments,” said RAMM Pharma Corp. CEO Jack Burnett.
RAMM Pharma is down 3.85 per cent, with shares of the company trading at C$1.00 at 10:56 am ET.
